Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Jonathan Matthew Hernandez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7529-0557; OpenAlex author ID A5033639338, A5106038406. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers

Papers 13

  1. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  2. ALLIANCE A021806: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15817-5↗
  3. A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Res… Co-author DOI 10.1245/s10434-022-12742-3↗
  4. A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial). Co-author DOI 10.1245/s10434-022-11917-2↗
  5. The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled Water or Sali… Co-author DOI 10.1245/s10434-022-11978-3↗
  6. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-3624↗
  7. Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic c… Last author DOI 10.21037/jgo.2020.02.01↗
  8. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… First author DOI 10.1016/j.hpb.2017.12.010↗
  9. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Co-author DOI 10.1038/ncb3169↗
  10. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Co-author DOI 10.1097/sla.0000000000000310↗
  11. Pancreatic adenocarcinoma: complete tumor extirpation improves survival benefit despite larger tumors for patients who undergo distal pancreatectomy and splene… First author DOI 10.1007/s11605-011-1765-6↗
  12. Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status. First author DOI 10.1016/j.amjsurg.2012.01.016↗
  13. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenoc… First author DOI 10.1111/j.1477-2574.2011.00304.x↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Areeba Saif · 3 shared papers, 2022–2023 · strength 0.55
  2. Martha E. Teke · 2 shared papers, 2022 · strength 0.36
  3. Cristina R. Ferrone · 1 shared paper, 2024 · strength 0.24
  4. Alyssa V. Eade · 1 shared paper, 2024 · strength 0.24
  5. Akhil Chawla · 1 shared paper, 2024 · strength 0.24
  6. Jeremy L. Davis · 2 shared papers, 2020 · strength 0.20
  7. Bradley A. Erickson · 1 shared paper, 2023 · strength 0.19
  8. William Adrian Hall · 1 shared paper, 2023 · strength 0.19
  9. Douglas B. Evans · 1 shared paper, 2023 · strength 0.19
  10. Susan Tsai · 1 shared paper, 2023 · strength 0.19
  11. Mandana Kamgar · 1 shared paper, 2023 · strength 0.19
  12. Kim A. Reiss · 1 shared paper, 2022 · strength 0.19
  13. Harish Lavu · 1 shared paper, 2022 · strength 0.17
  14. Avinoam Nevler · 1 shared paper, 2022 · strength 0.17
  15. Shreya Gupta · 1 shared paper, 2020 · strength 0.11
  16. Alexander S. Rosemurgy · 3 shared papers, 2011–2012 · strength 0.10
  17. Bruno Costa‐Silva · 2 shared papers, 2015–2018 · strength 0.10
  18. David C. Lyden · 2 shared papers, 2015–2018 · strength 0.10
  19. Alexandre Doussot · 2 shared papers, 2015–2018 · strength 0.10
  20. William R. Jarnagin · 2 shared papers, 2015–2018 · strength 0.10
  21. Freddy E. Escorcia · 1 shared paper, 2020 · strength 0.09
  22. Tim F. Greten · 1 shared paper, 2020 · strength 0.09
  23. Changqing Xie · 1 shared paper, 2020 · strength 0.09
  24. Austin G. Duffy · 1 shared paper, 2020 · strength 0.09
  25. Paul G. Toomey · 2 shared papers, 2012 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.